SCHEMBL7124104

SCHEMBL7124104

Cn1c2c(c(=O)n(Cc3ccc(F)c(F)c3)c1=O)C=C(C(=O)OCc1ccc(F)cc1)CS2(O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.37
TP53 P04637 3/20 0.36
LMNA P02545 1/20 0.36
ALDH1A1 P00352 3/20 0.33
PKM P14618 3/20 0.33
MAPT P10636 3/20 0.33
TSHR P16473 2/20 0.33
KDM4E B2RXH2 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA2B P29275 1/20 0.33
ADORA1 P30542 1/20 0.33
GPBAR1 Q8TDU6 1/20 0.32
MEN1 O00255 1/20 0.32
USP2 O75604 1/20 0.32
MAPK1 P28482 1/20 0.32
KMT2A Q03164 1/20 0.32
PTGDR2 Q9Y5Y4 1/20 0.32
MMP1 P03956 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7123023 0.89 L3MBTL1 (0.42) TP53LMNAALDH1A1PKMTSHR
SCHEMBL7122539 0.86 KDM4E (0.40) TP53LMNAALDH1A1MAPTKDM4E
SCHEMBL6692406 0.85 ALDH1A1 (0.36) ALDH1A1TSHRPTGDR2
SCHEMBL7115999 0.84 TRPA1 (0.42) TP53LMNAALDH1A1PKMMAPT
SCHEMBL6695961 0.81 MMP1 (0.36) THRBTP53ALDH1A1MAPTKMT2A
SCHEMBL7114173 0.77 THRB (0.43) THRBTP53ALDH1A1MAPTKDM4E
SCHEMBL7126531 0.73 TRPA1 (0.53) TP53LMNAALDH1A1MAPTKDM4E
SCHEMBL7116975 0.71 TP53 (0.35) THRBTP53LMNAALDH1A1PKM
SCHEMBL7131191 0.71 MMP1 (0.40) LMNAALDH1A1MAPTKDM4ENPSR1
SCHEMBL7126749 0.71 TRPA1 (0.42) LMNAALDH1A1PKMMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP25 THRB 4677/4885TP53 2986/4885LMNA 3842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.